Citation: | CHEN Juanjuan, LYU Chaoyang, DENG Manqing. Clinical characteristics of proximal tubular acidosis induced by deferasirox in children with β-thalassemia major[J]. Journal of Clinical Medicine in Practice, 2024, 28(24): 124-128. DOI: 10.7619/jcmp.20243626 |
To analyze the clinical characteristics of proximal tubular acidosis induced by deferasirox in children with β-thalassemia major.
This study retrospectively analyzed the clinical manifestations, laboratory test results, radiological features, treatment methods and outcomes of proximal tubular acidosis in 5 children with β-thalassemia major.
Five patients aged 5 to 16 years, included 2 males and 3 females. Two patients were diagnosed with Fanconi syndrome. Four patients received deferasirox doses exceeding the conventional dose, including one with a rapid decline in ferritin levels. Gastrointestinal symptoms were the initial manifestations in 3 patients, while only mild anorexia was observed in 2 patients. There were significant correlations between the severity of clinical manifestations, the degree of acidosis and its duration. All patients had abnormally elevated urine β2-microglobulin levels, and 4 patients had hepatic iron deposition. After reducing or discontinuing deferasirox and providing symptomatic treatment, the renal tubular function of all 5 patients gradually recovered.
Proximal tubular acidosis induced by deferasirox in patients with β-thalassemia major can manifest as partial or complete proximal tubular acidosis, which may be associated with high-dose deferasirox administration and rapid decreases in body iron levels. Regular monitoring of relevant indicators is recommended for children receiving long-term deferasirox treatment. Once proximal tubular acidosis is detected, drug dosage adjustment or discontinuation should be promptly implemented, and renal tubular function can recover in most patients.
[1] |
PAPNEJA K, BHATT M D, KIRBY-ALLEN M, et al. Fanconi syndrome secondary to deferasirox in diamond-blackfan Anemia: case series and recommendations for early diagnosis[J]. Pediatr Blood Cancer, 2016, 63(8): 1480-1483. doi: 10.1002/pbc.25995
|
[2] |
FRASER J, BROOK R, HE T, et al. Deferasirox-induced liver injury and Fanconi syndrome in a beta-thalassemia major male[J]. BMJ Case Rep, 2020, 13(7): e234542. doi: 10.1136/bcr-2020-234542
|
[3] |
DELL'ORTO V G, BIANCHETTI M G, BRAZZOLA P. Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature[J]. J Clin Pharm Ther, 2013, 38(6): 526-527. doi: 10.1111/jcpt.12095
|
[4] |
刘星星, 李宇红, 李悦. 地拉罗司致患儿肾小管损害一例[J]. 临床药物治疗杂志, 2022, 20(5): 87-89.
|
[5] |
王海燕, 赵明辉. 肾脏病学[M]. 4版. 北京: 人民卫生出版社, 2020: 123-126.
|
[6] |
YUI J C, GEARA A, SAYANI F. Deferasirox-associated Fanconi syndrome in adult patients with transfusional iron overload[J]. Vox Sang, 2021, 116(7): 793-797. doi: 10.1111/vox.13064
|
[7] |
PANDIT S, SONI D, KRISHNAMURTHY B, et al. Comparison of WHO-UMC and naranjo scales for causality assessment of reported adverse drug reactions[J]. J Patient Saf, 2024, 20(4): 236-239. doi: 10.1097/PTS.0000000000001213
|
[8] |
CHUANSUMRIT A, SONGDEJ D, SIRACHAINAN N, et al. Efficacy and safety of a dispersible tablet of GPO-deferasirox monotherapy among children with transfusion-dependent thalassemia and iron overload[J]. Hemoglobin, 2024, 48(1): 47-55. doi: 10.1080/03630269.2024.2311360
|
[9] |
BIRD S T, SWAIN R S, TIAN F, et al. Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies[J]. Lancet Child Adolesc Health, 2019, 3(1): 15-22. doi: 10.1016/S2352-4642(18)30335-3
|
[10] |
NIÑO TARAVILLA C, CERVERA BRAVO Á, OTAOLA ARCA H, et al. Deferasirox and Complex Proximal Tubulopathy. Presentation of two clinical cases[J]. Andes Pediatr, 2021, 92(4): 584-589. doi: 10.32641/andespediatr.v92i4.3154
|
[11] |
RAFAT C, FAKHOURI F, RIBEIL J A, et al. Fanconi syndrome due to deferasirox[J]. Am J Kidney Dis, 2009, 54(5): 931-934. doi: 10.1053/j.ajkd.2009.03.013
|
[12] |
KHAN I, MUHAMMAD M, PATEL J. Deferasirox-a rarer cause of Fanconi syndrome[J]. J Community Hosp Intern Med Perspect, 2019, 9(4): 358-359. doi: 10.1080/20009666.2019.1650592
|
[13] |
陈玲, 侯香萍, 肖永宏. 胸腔积液细胞学发现β地中海贫血髓外造血1例[J]. 检验医学与临床, 2023, 20(17): 2623-2624. doi: 10.3969/j.issn.1672-9455.2023.17.040
|
[14] |
刘文彦, 李宇红, 徐海霞, 等. 20例儿童原发性远端肾小管酸中毒的临床表型与基因分析[J]. 实用临床医药杂志, 2023, 27(6): 123-127. doi: 10.7619/jcmp.20223755
|
[15] |
李铮. 早期肾脏损伤尿液检测指标的应用现状及研究进展[J]. 医疗装备, 2021, 34(7): 190-191. doi: 10.3969/j.issn.1002-2376.2021.07.092
|
[16] |
CETINKAYA P U, AZIK F M, KARAKUS V, et al. β2-microglobulin, neutrophil gelatinase-associated lipocalin, and endocan values in evaluating renal functions in patients with β-thalassemia major[J]. Hemoglobin, 2020, 44(3): 147-152. doi: 10.1080/03630269.2020.1766486
|
[17] |
FUCILE C, MATTIOLI F, MARINI V, et al. What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis[J]. Ther Clin Risk Manag, 2018, 14: 1649-1655. doi: 10.2147/TCRM.S170761
|
[18] |
EVEN-OR E, BECKER-COHEN R, MISKIN H. Deferasirox treatment may be associated with reversible renal Fanconi syndrome[J]. Am J Hematol, 2010, 85(2): 132-134. doi: 10.1002/ajh.21588
|
[19] |
GRANGÉ S, BERTRAND D M, GUERROT D, et al. Acute renal failure and Fanconi syndrome due to deferasirox[J]. Nephrol Dial Transplant, 2010, 25(7): 2376-2378. doi: 10.1093/ndt/gfq224
|
[20] |
YACOBOVICH J, STARK P, BARZILAI-BIRENBAUM S, et al. Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox[J]. J Pediatr Hematol Oncol, 2010, 32(7): 564-567. doi: 10.1097/MPH.0b013e3181ec0c38
|
[21] |
WEI H Y, YANG C P, CHENG C H, et al. Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months[J]. Transfusion, 2011, 51(5): 949-954. doi: 10.1111/j.1537-2995.2010.02939.x
|
[22] |
RHEAULT M N, BECHTEL H, NEGLIA J P, et al. Reversible Fanconi syndrome in a pediatric patient on deferasirox[J]. Pediatr Blood Cancer, 2011, 56(4): 674-676. doi: 10.1002/pbc.22711
|
[23] |
MILAT F, WONG P, FULLER P J, et al. A case of hypophosphatemic osteomalacia secondary to deferasirox therapy[J]. J Bone Miner Res, 2012, 27(1): 219-222. doi: 10.1002/jbmr.522
|
[24] |
MURPHY N, ELRAMAH M, VATS H, et al. A case report of deferasirox-induced kidney injury and Fanconi syndrome[J]. WMJ, 2013, 112(4): 177-180. http://www.wisconsinmedicalsociety.org/_WMS/publications/wmj/pdf/112/4/177.pdf
|
[25] |
DEE C M A, CHEUK D K L, HA S Y, et al. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia[J]. Br J Haematol, 2014, 167(3): 434-436. doi: 10.1111/bjh.13002
|
[26] |
CHUANG G T, TSAI I J, TSAU Y K, et al. Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use[J]. Nephrology, 2015, 20(12): 931-935. doi: 10.1111/nep.12523
|
1. |
刘晨,叶健文,王雪梅,李桦. 血清中微小RNA-506、微小RNA-934水平对胰腺癌患者术后生存结局的预测价值. 实用临床医药杂志. 2024(05): 40-43 .
![]() | |
2. |
谢扬帆,曹玲敏,汪雪媛,林川,黄海溶. 中国胰腺癌患者肠道菌群多样性组成谱的系统评价. 中国循证医学杂志. 2023(02): 186-190 .
![]() | |
3. |
姚钧天,刘亮,郭津生. 胰腺癌的诊断与精准治疗. 西南医科大学学报. 2023(02): 110-115 .
![]() | |
4. |
丛鹏,苏祥杰,李永. 微小RNA-433-3p靶向滑蛋白调控胰腺癌PANC-1细胞恶性生物学行为的研究. 实用临床医药杂志. 2023(14): 19-25 .
![]() | |
5. |
高春,江晶晶,冯富娟,甄英丽,张久聪,蒋觐阳. 基于CiteSpace的胰腺癌免疫治疗研究热点的可视化分析. 胃肠病学和肝病学杂志. 2023(11): 1262-1270 .
![]() |